PURPOSE: To retrospectively determine the incidence and patterns (in-field, marginal, or out-of-field) of locoregional gastric cancer recurrence in patients who received preoperative chemoradiotherapy and to determine the outcome in these patients. METHODS AND MATERIALS: Between 1994 and 2004, 149 patients with gastric carcinoma were treated according to institutional protocols with preoperative chemoradiotherapy. Ultimately, 105 patients had an R0 resection. Of these 105 patients, 65 received preoperative chemotherapy followed by chemoradiotherapy and 40 received preoperative chemoradiotherapy. Most (96%) of these patients received 5-fluorouracil-based chemotherapy during radiotherapy, and the median radiation dose was 45 Gy. We retrospectively identified and classified the patterns of locoregional recurrence. RESULTS: The 3-year actuarial incidence of locoregional recurrence was 13%, with locoregional disease recurring as any part of the failure pattern in 14 patients. Most (64%) of the evaluable locoregional recurrences were in-field. Of the 4 patients with a marginal recurrence, 2 had had inadequate coverage of the regional nodal volumes on their oblique fields. The pathologic complete response rate was 23%. A pathologic complete response was the only statistically significant predictor of locoregional control. CONCLUSION: Patients with gastric cancer who received preoperative chemoradiotherapy had low rates of locoregional recurrence. This strategy merits prospective multi-institutional and randomized evaluation.
PURPOSE: To retrospectively determine the incidence and patterns (in-field, marginal, or out-of-field) of locoregional gastric cancer recurrence in patients who received preoperative chemoradiotherapy and to determine the outcome in these patients. METHODS AND MATERIALS: Between 1994 and 2004, 149 patients with gastric carcinoma were treated according to institutional protocols with preoperative chemoradiotherapy. Ultimately, 105 patients had an R0 resection. Of these 105 patients, 65 received preoperative chemotherapy followed by chemoradiotherapy and 40 received preoperative chemoradiotherapy. Most (96%) of these patients received 5-fluorouracil-based chemotherapy during radiotherapy, and the median radiation dose was 45 Gy. We retrospectively identified and classified the patterns of locoregional recurrence. RESULTS: The 3-year actuarial incidence of locoregional recurrence was 13%, with locoregional disease recurring as any part of the failure pattern in 14 patients. Most (64%) of the evaluable locoregional recurrences were in-field. Of the 4 patients with a marginal recurrence, 2 had had inadequate coverage of the regional nodal volumes on their oblique fields. The pathologic complete response rate was 23%. A pathologic complete response was the only statistically significant predictor of locoregional control. CONCLUSION:Patients with gastric cancer who received preoperative chemoradiotherapy had low rates of locoregional recurrence. This strategy merits prospective multi-institutional and randomized evaluation.
Authors: J A Ajani; P F Mansfield; C H Crane; T T Wu; S Lunagomez; P M Lynch; N Janjan; B Feig; J Faust; J C Yao; R Nivers; J Morris; P W Pisters Journal: J Clin Oncol Date: 2005-02-20 Impact factor: 44.544
Authors: Steven C Cunningham; Farin Kamangar; Min P Kim; Sommer Hammoud; Raqeeb Haque; Anirban Maitra; Elizabeth Montgomery; Richard E Heitmiller; Michael A Choti; Keith D Lillemoe; John L Cameron; Charles J Yeo; Richard D Schulick Journal: J Gastrointest Surg Date: 2005 May-Jun Impact factor: 3.452
Authors: Michael D'Angelica; Mithat Gonen; Murray F Brennan; Alan D Turnbull; Manjit Bains; Martin S Karpeh Journal: Ann Surg Date: 2004-11 Impact factor: 12.969
Authors: J A Ajani; P F Mansfield; N Janjan; J Morris; P W Pisters; P M Lynch; B Feig; R Myerson; R Nivers; D S Cohen; L L Gunderson Journal: J Clin Oncol Date: 2004-07-15 Impact factor: 44.544
Authors: L Ceniceros; A Chopitea; F Pardo; F Rotellar; L Arbea; J J Sola; J C Subtil; B Sangro; A Benito; J L Hernández-Lizoain; J Rodríguez Journal: Clin Transl Oncol Date: 2017-10-17 Impact factor: 3.405
Authors: Milan Vošmik; Jan Laco; Igor Sirák; Josef Dvořák; Petr Lochman; Miroslav Hodek; Petra Malá; Stanislav Rejchrt; Rudolf Repák; Michal Leško; Alexander Ferko; Aleš Ryška; Bohuslav Melichar; Jiří Petera Journal: Pathol Oncol Res Date: 2017-05-27 Impact factor: 3.201
Authors: Tatiana Conrad; Steve MacLellan; Zahra Kassam; Helen Mackay; Ida Khalili; Jenna Sykes; Tom Purdie; Allan Okrainec; Jolie Ringash Journal: Gastric Cancer Date: 2015-09-11 Impact factor: 7.370
Authors: Casey J Allen; Alisa N Blumenthaler; Grace L Smith; Prajnan Das; Bruce D Minsky; Mariela Blum; Jaffer Ajani; Paul F Mansfield; Naruhiko Ikoma; Brian D Badgwell Journal: Ann Surg Oncol Date: 2020-07-21 Impact factor: 5.344
Authors: Joseph M Pepek; Junzo P Chino; Christopher G Willett; Manisha Palta; Dan G Blazer Iii; Douglas S Tyler; Hope E Uronis; Brian G Czito Journal: Radiat Oncol Date: 2013-01-04 Impact factor: 3.481